COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk CEO Mike

Doustdar said on Wednesday that ‌the price reductions for ​its

obesity drug Wegovy ‍in the U.S. ⁠are "painful" ⁠for the company's

financial results ‌but he ​hopes that they will be an ⁠investment

in ‍the ​future as many more people will be able ‍to get access to

the medicines as a result.

Doustdar was speaking with ​journalists ‍after the company on

Tuesday gave ​a far worse-than-expected outlook for 2026 and

flagged a tough weight-loss market battle ahead as ​prices come

under pressure.